United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 304.5 USD -0.62% Market Closed
Market Cap: 13.7B USD

EV/EBITDA
Enterprise Value to EBITDA

7
Current
8.1
Median
5.1
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
7
=
Enterprise Value
10.4B USD
/
EBITDA
1.5B USD
EBITDA Growth EV/EBITDA to Growth
US
United Therapeutics Corp
NASDAQ:UTHR
Average EV/EBITDA: 15
7
2%
3.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 789.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580 N/A N/A
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.5 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
6.2
2-Years Forward
EV/EBITDA
6.1
3-Years Forward
EV/EBITDA
6.5